This Obscure AI Stock Following Intuitive Surgical's Path

Now, I've found an obscure AI stock following its path. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from The Oxford Club Dear Reader, Remember Intuitive Surgical's rise of 18,000% over two decades? It used new tech to transform surgery. Now, I've found an obscure AI stock following its path. This company brought the first AI-designed drug to clinical trials. It's lined up major pharma partnerships together worth over $7 billion. Yet with a market cap of only $700 million, it trades for under $10 a share. My new video reveals why this little-known leader in AI drug discovery could hand investors incredible profits in the years ahead. [[Click here for the details.]] Good investing, Alexander Green Chief Investment Strategist, The Oxford Club

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.   This message is a paid advertisement sent on behalf of The Oxford Club, a third-party advertiser of The Early Bird and MarketBeat.   If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from The Early Bird, you can unsubscribe.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: I left my hedge fund and built a stock prediction system (Click to Opt-in)